TENAX THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
TENAX THERAPEUTICS, INC. (TENX) had Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number of 20.93 million shares as of 2021-12-31, per its 10-K filed 2022-03-29.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber · last filed 2022-03-29
- 2021-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 20.93M shares.
- 2021-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 15.80M shares.
- 2020-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 16.60M shares.
- 2020-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 20.95M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number |
|---|---|
| 2021-12-31 | 20.93M shares 10-K · filed 2022-03-29 |
| 2021-03-31 | 15.80M shares 10-Q · filed 2021-05-17 |
| 2020-12-31 | 16.60M shares 10-K · filed 2022-03-29 |
| 2020-09-30 | 20.95M shares 10-Q · filed 2020-11-16 |
| 2020-06-30 | 12.27M shares 10-Q · filed 2020-08-14 |
| 2020-03-31 | 14.36M shares 10-Q · filed 2020-05-15 |
| 2019-12-31 | 10.52M shares 10-K · filed 2022-03-29 |
| 2019-09-30 | 10.52M shares 10-Q · filed 2019-11-14 |
| 2019-06-30 | 10.64M shares 10-Q · filed 2019-08-14 |
| 2019-03-31 | 10.64M shares 10-Q · filed 2019-05-15 |
| 2018-12-31 | 10.69M shares 10-K/A · filed 2021-04-16 |
| 2017-12-31 | 120.77K shares 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |